Pharmacological antithrombotic adjuncts to percutaneous coronary intervention
Authors: Lucking, Andrew J1; Newby, David E2
Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 6, April 2007 , pp. 759-776(18)
Publisher: Informa Healthcare
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Stent thrombosis is the major cause of early adverse events during percutaneous coronary intervention. Its incidence has fallen considerably in recent years, principally due to the introduction of effective antithrombotic therapies. The selection of an appropriate antithrombotic regimen is critical in achieving a balance between reducing ischaemic events and minimising bleeding complications in patients undergoing percutaneous coronary intervention. In this article, evidence for the role of antiplatelet and anticoagulant therapies is discussed, including the thienopyridines, glycoprotein IIb/IIIa receptor antagonists, direct thrombin inhibitors and pentasaccharides.Keywords: anticoagulation; antiplatelet treatment; percutaneous coronary intervention
Document Type: Research article
DOI: 10.1517/14656566.8.6.759
Affiliations: 1: 1Clinical Research Fellow, The University of Edinburgh, Room SU.305, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SU, Scotland., Email: andrew.lucking@btinternet.com 2: 2Professor of Cardiology, Edinburgh University, Centre for Cardiovascular Science, Edinburgh, Scotland
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help